Physician profile
Haris Ali
NPI 1467672907
$310,073.50
in general payments reported to CMS, 2019-2025
20 companies · $28K in 2025
The $28K reported for 2025 was more than what 88% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $31K · 2021: $28K · 2022: $54K · 2023: $62K · 2024: $66K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $37K · Travel and Lodging: $11K · Food and Beverage: $3,416 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,918.50 |
| Consulting Fee | $36,633.75 |
| Travel and Lodging | $10,994.56 |
| Food and Beverage | $3,416.14 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $147,283.11 | 2019-2025 | Jakafi, Niktimvo, Jakafi |
| Glaxosmithkline, LLC. | $44,801.71 | 2022-2025 | Ojjaara |
| Pharmaessentia USA Corporation | $32,512.07 | 2022-2025 | Besremi |
| Celgene Corporation | $28,637.92 | 2019-2022 | |
| Sobi, INC | $25,937.50 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $10,067.29 | 2023-2025 | Xpovio |
| Blueprint Medicines Corporation | $8,695.86 | 2022 | |
| Geron Corporation | $3,334.84 | 2025 | Imetelstat |
| Novartis Pharmaceuticals Corporation | $2,725.89 | 2021-2025 | |
| Abbvie INC. | $2,344.71 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,133.51 | 2022-2024 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $1,192.98 | 2019-2022 | |
| Inari Medical, INC. | $189.14 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $164.96 | 2022-2024 | Calquence |
| Genzyme Corporation | $18.40 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.36 | 2023 | Venclexta |
| Amgen INC. | $15.25 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.